FDA Approves Pluvicto for Hormone-Sensitive Prostate Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Pluvicto for Hormone-Sensitive Prostate Cancer

The approval is based on phase 3 PSMAddition results showing reduced risk of disease progression or death with Pluvicto plus standard of care compared with standard of care alone, according to Novartis.

  • By

  • Kathryn Wighton

  • August 3, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Pluvicto for Hormone-Sensitive Prostate Cancer

  • by Kathryn Wighton

  • August 3, 2026

Related Content

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.